Glucagon-like peptide-1 receptor agonist
| Subclass of | anti-diabetic medication  |
|---|---|
| Agonist of | glucagon-like peptide-1 |
Glucagon-like peptide-1 (GLP-1) receptor agonists, dem sanso know as GLP-1 agonists, GLP-1RAs, den informally as simply GLP-1s, be a class of medications wey activate de GLP-1 receptor, wey dey cause reduced blood sugar, reduced appetite, den reduced energy intake. GLP-1 analogs be molecules wey be structurally almost identical to de endogenous GLP-1 hormone. Incretin mimetics be substances wey mimic de actions of incretin hormones such as GLP-1 den GIP.
Originally dem develop to treat type 2 diabetes, sam GLP-1 agonists be approved to treat obesity. Dem dey mimic de actions of de endogenous incretin hormone GLP-1, wich be released insyd de small intestine den fi inhibit glucagon release den increase insulin secretion.[1]
GLP-1 receptor agonists be used to treat type 2 diabetes den obesity, wey dem be under study for treatment of metabolic dysfunction–associated steatotic liver disease, polyendocrine metabolic ovarian syndrome, den diseases of de reward system, such as addictions (especially from ultra-processed foods).[2]
References
[edit | edit source]- ↑ Ross, Stuart A.; Ekoé, Jean-Marie (July 2010). "Incretin agents in type 2 diabetes". Canadian Family Physician. 56 (7): 639–648. PMC 2922799. PMID 20631270.
- ↑ "David Kessler on What Doctors and Patients Should Know About GLP-1 Drugs | Harvard Medicine Magazine". magazine.hms.harvard.edu (in English). Retrieved 8 March 2026.
External links
[edit | edit source]
- Gonzalez-Rellan, Maria J.; Drucker, Daniel J. (July 2025). "The expanding benefits of GLP-1 medicines". Cell Reports Medicine. 6 (7) 102214. doi:10.1016/j.xcrm.2025.102214. PMC 12281309. PMID 40669447.